Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Not Confirmed
Not Confirmed
26-28 May, 2026
Not Confirmed
Not Confirmed
27-28 May, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston Summit
Not Confirmed
Contact SupplierPEGS Boston Summit
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Pharmex Middle EastPharmex Middle East
Industry Trade Show
Not Confirmed
26-28 May, 2026
Industry Trade Show
Not Confirmed
27-28 May, 2026
Digital content
NEWS #PharmaBuzz
31 Mar 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260331718599/en/CellCentric-Initiates-DOMMINO-1-a-Pivotal-Phase-2-Clinical-Trial-of-Inobrodib-in-Combination-with-Pomalidomide-and-Dexamethasone-InoPd-in-Relapsed-or-Refractory-Multiple-Myeloma
20 May 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/pfizer-backed-cellcentric-secures-120m-further-myeloma-trials
02 Apr 2025
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/british-biotech-cellcentric-expands-boston-plans-grow-late-stage-clinical-development
04 Nov 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cellcentric-to-present-inobrodib-phase-i-multiple-myeloma-efficacy-and-safety-data-at-the-american-society-of-haematology-301668106.html
06 Apr 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cellcentric-strengthens-leadership-team-301518268.html
26 Jan 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/cellcentric-secures-investment-from-american-cancer-societys-impact-venture-capital-fund-to-advance-inobrodib-its-ground-breaking-p300cbp-targeted-therapy-301467871.html
Drugs in Development
Details:
The Series D financing for Inobrodib will support the development of therapies targeting CREBBP|EP300 in multiple myeloma.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: CS1477
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Venrock Healthcare Capital Partners
Deal Size: $220.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing May 06, 2026
CellCentric Raises $220M for Inobrodib Trials in Multiple Myeloma
Details : The Series D financing for Inobrodib will support the development of therapies targeting CREBBP|EP300 in multiple myeloma.
Product Name : CS1477
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 06, 2026
Details:
Inobrodib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Multiple Myeloma.
Lead Product(s): Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 31, 2025
Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Details : Inobrodib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 31, 2025
Details:
The funding will further support the advancement of CellCentric’s novel small molecule oral p300/CBP inhibitor, CCS1477 (inobrodib), for the treatment of multiple myeloma.
Lead Product(s): Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: RA Capital Management
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing May 19, 2025
Lead Product(s) : Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : RA Capital Management
Deal Size : $120.0 million
Deal Type : Series C Financing
Pfizer-backed CellCentric Secures $120M for Ph. 3 Myeloma Trial
Details : The funding will further support the advancement of CellCentric’s novel small molecule oral p300/CBP inhibitor, CCS1477 (inobrodib), for the treatment of multiple myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
May 19, 2025
Details:
The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.
Lead Product(s): Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 11, 2023
Lead Product(s) : Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
CellCentric Announces $25m Strategic Investment from Pfizer
Details : The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 11, 2023
Details:
Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.
Lead Product(s): Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 04, 2022
Lead Product(s) : Inobrodib,Dexamethasone,Pomalidomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2022
Details:
The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Investments Limited.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: BrightEdge
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 26, 2022
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : BrightEdge
Deal Size : Undisclosed
Deal Type : Funding
CellCentric Secures Investment from The American Cancer Society’s Impact Venture Capital Fund
Details : The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Inve...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 26, 2022
Details:
CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with standard of care agents.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Morningside Ventures
Deal Size: $33.0 million Upfront Cash: Undisclosed
Deal Type: Financing October 22, 2020
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Morningside Ventures
Deal Size : $33.0 million
Deal Type : Financing
Details : CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with stan...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 22, 2020
Details:
CellCentric has signed an agreement with the Prostate Cancer Clinical Trial Consortium to help select and manage US sites for the ongoing evaluation of CCS1477.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Recipient: Prostate Cancer Clinical Trial Consortium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 07, 2020
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Prostate Cancer Clinical Trial Consortium
Deal Size : Undisclosed
Deal Type : Agreement
Cellcentric Signs Deal for Clinical Trial Expansion into the US
Details : CellCentric has signed an agreement with the Prostate Cancer Clinical Trial Consortium to help select and manage US sites for the ongoing evaluation of CCS1477.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 07, 2020
Details:
CCS1477 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hematologic Neoplasms.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2019
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Details : CCS1477 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 28, 2019
Details:
CCS1477 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Lead Product(s): Inobrodib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2018
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Evaluate CCS1477 in Advanced Tumours
Details : CCS1477 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2018
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
